GeneDx Holdings Corp Stock Price, News & Analysis

GeneDx (Nasdaq: WGS) will present research at the American Society of Human Genetics Annual Meeting on October 15–16, 2025 highlighting results enabled by GeneDx Infinity, a dataset of nearly 1 million exomes/genomes and over 7 million phenotypic datapoints. GeneDx will showcase 14 studies across genomic newborn screening, neurodevelopmental disorders, diagnostic technologies, long‑read sequencing validation, and machine learning applications.

Key disclosed results include a study of >62,000 individuals with autism identifying core genes and genetic correlations with other disorders, GUARDIAN gNBS data from 15,000 newborns with high enrollment and follow‑up outcomes, and benchmarking that shows high concordance of CNV detection between exome/genome sequencing and chromosomal microarray.

GeneDx (NASDAQ: WGS) will report Q3 2025 financial results before the market opens on Tuesday, October 28, 2025. Management will host a conference call at 8:30 a.m. Eastern Time the same day to discuss financial and operating results. Investors must register online to access the call. A live and archived webcast will be available in the Events section of the GeneDx investor relations website at https://ir.genedx.com/. The announcement provides timing, registration requirement, and webcast access details for shareholders and analysts.

GeneDx (Nasdaq: WGS) has announced BEACONS (Building Evidence and Collaboration for GenOmics in Nationwide Newborn Screening), the first U.S. multi-state genomic newborn screening initiative, supported by a $14.4 million NIH award.

The initiative, led by Mass General Brigham and Ariadne Labs, will enroll up to 30,000 newborns across 10 states over three years. GeneDx will perform genomic sequencing and interpretation, leveraging their expertise as the company that has diagnosed more children with rare diseases and screened more newborns with genomic sequencing in the U.S.

The project aims to pilot the integration of whole genome sequencing into existing state newborn screening systems, with potential for national scaling. The study will focus on identifying treatable genetic conditions early in life, guided by rare disease advocates, state public health laboratories, and prior research evidence.

GeneDx (Nasdaq: WGS), a leader in genomic insights, has appointed Lisa Gurry as Chief Business Officer (CBO) in a newly-created role. Gurry, a Truveta co-founder and former Microsoft leader, will spearhead GeneDx's transformation by advancing data and information services across biopharma and health systems.

Gurry will leverage GeneDx Infinity™, the company's rare disease dataset containing nearly one million exomes and genomes paired with over seven million phenotypic datapoints. Her responsibilities include overseeing strategic business operations, partnership models, and communications to unlock the dataset's potential for accelerating diagnoses and drug development.

GeneDx (Nasdaq: WGS) announced the introduction of GeneDx Infinity™, its proprietary dataset, at the American Academy of Pediatrics National Conference. Infinity represents the industry's largest rare disease dataset, powering the company's ExomeDx™ and GenomeDx™ testing solutions.

The dataset includes data from over 2.5 million genomic patients, featuring nearly 1 million exomes and genomes, 7 million phenotypic data points, and over 50% non-European representation. GeneDx leads the U.S. clinical exome and genome market with 80% of geneticists choosing the company for superior diagnostic yield.

The announcement follows AAP's recent guidance recommending exome and genome sequencing as first-tier tests for children with global developmental delay or intellectual disability.

GeneDx (Nasdaq: WGS), a genomic insights company, has appointed Dr. Thomas Fuchs, Chief AI Officer at Eli Lilly, to its board of directors. Dr. Fuchs brings extensive experience in AI and machine learning for diagnostic medicine, having previously served as Dean for AI and Human Health at Mount Sinai and founded multiple companies including Paige AI.

The appointment aligns with GeneDx's AI-driven initiatives, including their recent launch of Multiscore, an AI-powered genetic analysis tool, and the acquisition of Fabric Genomics. These strategic moves strengthen GeneDx's position in using AI to improve rare disease diagnosis and patient outcomes.

GeneDx (Nasdaq: WGS), a genomic insights company, has announced its participation in three upcoming investor conferences in August and September 2025. The company will participate in fireside chat sessions at the Canaccord Genuity Growth Conference (August 12), Wells Fargo Healthcare Conference (September 4), and Morgan Stanley Global Healthcare Conference (September 8).

All presentations will be accessible through live and archived webcasts on the company's investor relations website.

GeneDx (NASDAQ: WGS) reported strong Q2 2025 financial results, with revenue reaching $102.7 million, marking a 49% year-over-year increase. The company's core exome and genome test revenue grew 69% year-over-year to $85.9 million, with test volume increasing 28% to 23,102 tests.

Key financial metrics include an expanded adjusted gross margin of 71% and an adjusted net income of $15.0 million, marking the fourth consecutive profitable quarter. The company has raised its full-year 2025 guidance to $400-415 million in revenue.

Strategic developments include the acquisition of Fabric Genomics and a significant endorsement from the American Academy of Pediatrics, now recommending exome and genome sequencing as first-tier tests for children with developmental delays. The company has also expanded Medicaid coverage to 35 states for pediatric outpatient testing.

GeneDx (Nasdaq: WGS), a genomic insights company, has scheduled its Q2 2025 financial results announcement for Tuesday, July 29, 2025, before market opening. The company will host a conference call at 8:30 a.m. Eastern Time to discuss the quarter's financial and operating performance.

Investors must register online to participate in the conference call. Both live and archived versions of the webcast will be accessible through the "Events" section on GeneDx's investor relations website.